<DOC>
	<DOCNO>NCT02411136</DOCNO>
	<brief_summary>This study evaluate safety AMG 623 subject systemic lupus erythematosus . All subject receive 4 weekly dos study drug 3 week period , follow additional 28 week , total study duration 31 week .</brief_summary>
	<brief_title>A Study Examine Safety , Pharmacokinetics Pharmacodynamics AMG 623 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Men woman age 18 65 year old Diagnosis SLE Stable disease ; define change SLE therapy within previous 30 day . Up 5 mg/day incremental change prednisone therapy allow 30 day prior randomization SLE disease duration least 1 year , diagnose physician Current renal disease Signs symptoms viral bacterial infection within 30 day enrollment Any disorder ( include psychiatric ) , condition clinically significant disease ( diagnosis SLE ) would interfere study evaluation , completion and/or procedure per investigator 's discretion Administration 10 mg/day prednison ( equivalent ) 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>